Salicylic Acid

5
Salicylic Acid
Brands

DEA Class; Rx, OTC

Common Brand Names; Compound W, Compound W for Kids, Dr. Scholl’s Advanced Pain Relief Corn Removers, Dr. Scholl’s Callus Removers, Dr. Scholl’s Clear Away, Dr. Scholl’s Clear Away OneStep, Dr. Scholl’s Clear Away Plantar, Dr. Scholl’s Corn Removers, Dr. Scholl’s Moisturizing Corn Remover Kit, Dr. Scholl’s OneStep Corn Removers, DuoPlant, Durasal, Keralyt, Mediplast, Trans-Ver-Sal AdultPatch, Trans-Ver-Sal PediaPatch, Trans-Ver-Sal PlantarPatch, Sal-Acid, Virasal, Psoriasin Medicated Wash

  • Keratolytic Agents

salicylic acid acne (OTC)

Brand and Other Names: Neutrogena Body Clear Body Wash, Neutrogena Oil-Free Acne Wash, Neutrogena Oil-Free Acne Stress Control, Neutrogena Oil-Free Acne Wash Foam Cleanser, Neutrogena Rapid Clear Acne Defense Face Lotion, Neutrogena Rapid Clear Acne Eliminating Spot Gel, Clean & Clear Advantage 3-in1 Foaming Acne wash, Clean & Clear Deep Cleaning Astringent, Clean & Clear Blackhead Eraser Scrub, Clean & Clear Dual Action Moisturizer, Clean & Clear Advantage Mark Treatment, Clean and Clear Advantage Acne Control Moisturizer, Oxy Clinical Advanced Face Wash, Oxy Maximum Face Scrub, Oxy Maximum Hydrating Body Wash, Oxy Maximum Cleansing Pads, Oxy Clinical Hydrating Therapy, Oxy Clinical Foaming Face Wash, Palmers Skin Success Acne Medication Cleanser, Zapzyt Acne Wash, Zapzyt Pore Clearing Scrub, Clearasil Ultra Rapid Action Face Scrub, Clearasil Daily Clear Daily Pore Cleansing Pads, Clearasil Daily Clear Vanishing Acne Treatment Cream, Benzac Skin Balancing Foaming Cleanser 0.5%, Benzac Intensive Spot Treatment 2%, Benzac Blemish Clearing Hydrator 0.5%, Benzac Skin Refining Mask
  • Classes: Acne Agents, Topical

Oral retinoid; synthetic 13-cis isomer of naturally occurring tretinoin
Used primarily for severe, recalcitrant nodular acne
Due to teratogenicity potential, only available through isotretinoin iPLEDGE REMs program

Indicated for the treatment of severe recalcitrant cystic acne vulgaris (nodular acne) in patients with multiple inflammatory nodules with a diameter of at least 5 mm.

For the treatment of keratinization disorders including keratosis follicularis, lamellar ichthyosis, and pityriasis rubra pilaris.
For the treatment of juvenile chronic myelogenous leukemia (CML).
For the treatment of newly diagnosed, high-risk neuroblastoma following autologous bone marrow transplantation.
For the treatment of recurrent cervical cancer, in combination with interferon alfa.
For the adjuvant treatment of advanced squamous cell head and neck cancer, in combination with interferon alfa and vitamin E.
For the adjuvant treatment of aggressive squamous cell skin carcinoma, in combination with interferon alfa.

Hypersensitivity

Prolonged use or application to large areas (risk for salicylism)

Children < 2 years

Virasal

  • Impaired circulaiton (diabetes)
  • Warts with hair growth or on face
  • Birthmarks
  • Moles

Facial warts or warts on mucous membranes

Warts with hair growing from them

Genitals

Infected, reddened, or irritated areas

  • Stinging/burning of skin
  • Dizziness
  • Headache
  • Tinnitus
  • Mental confusion
  • Peeling
  • Scaling
  • Burning/irritaion on normal tissue at site of exposure
  • Hyperventilation

External topical use only

Avoid contact with eyes

Caution in infants, diabetics, or those with impaired circulation (diabetes)

Prolonged use over large areas, especially in children and those patients with significant renal or hepatic impairment, could result in salicylism

Avoid concomitant use of other drugs which may contribute to elevated serum salicylate levels when the potential for toxicity is present

In children <12 years and patients with renal or hepatic impairment, area to be treated should be limited and patient monitored closely for signs of salicylate toxicity, including nausea, vomiting, dizziness, loss of hearing, tinnitus, lethargy, hyperpnea, diarrhea, and psychic disturbances

In event of salicylic acid toxicity, discontinue use of SA 6%

Fluids should be administered to promote urinary excretion; treatment with sodium bicarbonate (oral or intravenous) should be instituted as appropriate

Patients should be cautioned against use of oral aspirin and other salicylate containing medications, such as sports injury creams, to avoid additional excessive exposure to salicylic acid

Where needed, aspirin should be replaced by alternative non-steroidal anti-inflammatory agent that is not salicylate based

Patients should be advised not to apply occlusive dressings, clothing or other occlusive topical products such as petrolatum-based ointments to prevent excessive systemic exposure to salicylic acid

Excessive application of product other than what is needed to cover affected area will not result in a more rapid therapeutic benefit

Due to potential risk of developing Reye’s syndrome, salicylate products should not be used in children and teenagers with varicella or influenza, unless directed by physician

Drug shown to be teratogenic in rats and monkeys; difficult to extrapolate from oral doses of acetylsalicylic acid used in these studies to topical administration as the oral dose to monkeys may represent six times the maximal daily human dose of salicylic acid when applied topically over a large body surface

Because of potential for serious adverse reactions in nursing infants from mother’s use of SA 6%, a decision should be made whether to discontinue nursing or discontinue drug, taking into account importance of drug to mother; if used by nursing mothers, should not be used on chest area to avoid accidental contamination of child

Adults

2 mg/kg/day PO (all formulations EXCEPT Absorica LD) for cystic acne; 1.6 mg/kg/day PO (Absorica LD) for cystic acne.

Geriatric

2 mg/kg/day PO (all formulations EXCEPT Absorica LD) for cystic acne; 1.6 mg/kg/day PO (Absorica LD) for cystic acne.

Adolescents

1 mg/kg/day PO (all formulations EXCEPT Absorica LD) for cystic acne; 0.8 mg/kg/day PO (Absorica LD) for cystic acne.

Children

12 years: 1 mg/kg/day PO (all formulations EXCEPT Absorica LD) for cystic acne; 0.8 mg/kg/day PO (Absorica LD) for cystic acne.
younger than 12 years: Safety and efficacy have not been established.

Infants

Safety and efficacy have not been established.

Neonates

Safety and efficacy have not been established.

Salicylic acid topical

topical liquid

  • 0.5%
  • 1%
  • 2%
  • 3%
  • 6%
  • 12.6%
  • 13.6%
  • 16.7%
  • 17%
  • 17.6%
  • 26%
  • 27.5%

gel

  • 2%
  • 6%
  • 17%

lotion

  • 3%
  • 6%

cream

  • 2%
  • 6%

aerosol/foam

  • 6%

soap

  • 2%
  • 3%

strips

  • 40%

pad

  • 40%

disk

  • 40%

plaster

  • 40%

patch

  • 15%
  • 40%

 

Salicylic acid acne

topical lotion

  • 0.5%

topical cleanser

  • 2%
  • 0.5%

topical toner/astringent

  • 2%

topical gel

  • 2%

topical pads

  • 2%

topical cream

  • 2%
  • 6%

topical foam/aerosol

  • 6%

topical bar soap

  • 2%

topical mask

  • 0.5% plus East Indian sandalwood oil and French clay
DrugsAce
Logo